Holen Sie sich die Stockscreener-App
0.00
100.00%
-0.5195
Handel nachbörslich:
.52
0.52
+
Oragenics Inc Aktie (OGEN) Neueste Nachrichten
Oragenics (OGEN) Slips to $0.53, Holding Key Support Despite 1.16% DeclineRange Breakout - vinanet.vn
Oragenics: Q2 Earnings Snapshot - AOL.com
Oragenics (OGEN) flags going concern risk with $4.7M loss and $3.9M cash - Stock Titan
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
OGEN Q2 2023 Earnings: Narrower EPS Beat Lifts Shares 2.0%Interim Report - vinanet.vn
Oragenics Inc. Revenue Breakdown – AMEX:OGEN - TradingView
Oragenics Inc (OGEN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Oragenics Inc (OGEN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Oragenics Inc (OGEN) Cash Flow - TradingKey
OGEN|Oragenics Inc|Price:0.507|Chg%:-0.004 - TradingKey
TradingKey - TradingKey
Oragenics Inc (OGEN) Valuation: PE, PB & Fair Value Analysis - TradingKey
OGEN Q2 2023 Earnings: EPS Surprises to the Upside Despite No RevenueRevenue Guidance Update - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beat on 50.65% Surprise but No Revenue; Stock DeclinesPost-Earnings Drift - vinanet.vn
OGEN Q2 2023 Earnings: EPS Beats Estimates by 50.65% Despite No Revenue, Stock DeclinesCost Structure Review - Vinanet
Oragenics Inc. (OGEN) Holds Near Support Amid Modest DeclineBPI Bear Correction - dars.gov.et
OGEN Q2 2023 Earnings: EPS Surprise Beats Estimates Despite Stock DeclineGuidance vs Actual - vinanet.vn
Oragenics Incto Receive Exclusive License - Moomoo
Form 4 Oragenics Inc For: 7 July By Investing.com - Investing.com Nigeria
Oragenics (OGEN) CFO receives 55,900 stock options at $0.59 exercise price - Stock Titan
ORAGENICS (OGEN) CFO reports initial holdings, including 10,000-share stock option grant - Stock Titan
Oragenics Activates All Australian Phase IIa Trial Sites for Concussion Drug ONP-002 - citybuzz -
Oragenics Achieves Full Activation of Australian Phase IIa Trial NetworkAll Three Sites Now Enrolling - The Manila Times
Oragenics Achieves Full Activation of Australian Phase IIa Trial Network — All Three Sites Now Enrolling - GlobeNewswire
Oragenics Appoints New Chief Financial Officer and Leader - TipRanks
Oragenics, Inc. Announces Appointment of John Spencer to Chief Financial Officer, Effective July 1, 2026 - marketscreener.com
OGEN Q2 2023 Earnings: EPS Beat Driven by Cost Control Amid Ongoing Clinical DevelopmentEarnings Forecast Report - dars.gov.et
Price to earnings forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Narrowed Loss Surpasses Estimates, Stock Declines Amid No RevenueEarnings Quality Analysis - DonanımHaber
OGEN Q2 2023 Earnings: Narrower-Than-Expected Loss as Shares Drift LowerAnalyst Consensus Shift - po-news-eg.net
Price to book forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to EBIT forward of Oragenics Inc. – AMEX:OGEN - TradingView
Enterprise value to revenue forward of Oragenics Inc. – AMEX:OGEN - TradingView
OGEN Q2 2023 Earnings: Significant EPS Beat Amidst No Revenue ReportedTrough Earnings Signal - dars.gov.et
Oragenics Inc (OGEN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Oragenics, Inc. Actuals & Estimates (AMEX:OGEN) - TradingView
Oragenics (OGEN) Sees Minor Pullback as Biotech Stock Holds Above Key SupportMA Cross Alert - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat as Operating Loss NarrowsPretax Income Report - po-news-eg.net
Oragenics Inc (OGEN) Institutional Confidence - TradingKey
Oragenics Inc. (OGEN) Holds Near $0.59 Support Amid Low Volatility – Key Levels in FocusEquity Put Call - dars.gov.et
OGENOragenics Inc Short Interest - Finviz
OGEN Q2 2023 Earnings: Narrower-than-Expected Loss Boosts Investor Sentiment Despite Stock DeclineGuidance Revision Trend - po-news-eg.net
Oragenics Inc (OGEN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Oragenics Inc (OGEN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Oragenics Inc (OGEN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Oragenics Inc (OGEN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OGEN Q2 2023 Earnings: EPS Beat Despite No Revenue, Stock DeclinesEarnings Yield Spread - newsline.com
Oragenics Inc. (OGEN) Slips 2% as Stock Hovers Near Key Support LevelMFI Overbought - dars.gov.et
OGEN Q2 2023 Earnings: EPS Beat on Lower-than-Expected Loss, But Stock DeclinesEarnings Volatility Report - newsline.com
OGEN Q2 2023 Earnings: Loss Narrower Than Expected but No Revenue, Stock DeclinesQuarterly Earnings Report - newsline.com
OGEN Q2 2023 Earnings: Narrower Loss Drives 5% Bounce on Surprise BeatRevenue Growth Report - newsline.com
Oragenics Inc. (OGEN) Gains Ground: Potential Breakout Above $0.65 in Sight?Swing Trade Setups - newsline.com
OGEN Q2 2023 Earnings: Smaller-Than-Expected Loss as Clinical Pipeline ProgressesProduct Revenue Analysis - newsline.com
Oragenics Inc. (OGEN) Edges Lower to $0.60, Testing Key Support LevelsEarnings Quality Factor - newsline.com
OGEN Q2 2023 Earnings: EPS Beats Estimates by Over 50% as Company Advances PipelineBanking Earnings Report - newsline.com
ORAGENICS INC (OGEN) Stock Chart - ChartMill
0.00%
3.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):